Longbio-b
Status: Publicly traded
Direct answer
Longbio-b is publicly traded on HKSE under the ticker 1779.HK.
Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.
Can you invest in Longbio-b?
Yes. Longbio-b trades publicly on HKSE as 1779.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Detailed equity research is provided by MarketSnap.